Endometrial Cancer Therapeutics Market to Register a Revenue CAGR of 4.8% by 2031 | Growth Plus Reports


Newark, New Castle, USA, May 31, 2023 (GLOBE NEWSWIRE) — The market analysis of the global endometrial cancer therapeutics market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 4.8% by 2031.

The global endometrial cancer therapeutics market is registering significant revenue growth, driven by advancements in treatment modalities, a rise in the incidence of endometrial cancer, and an increasing focus on early diagnosis and personalized treatment approaches. Endometrial cancer is a common gynecological malignancy that affects the lining of the uterus. The market is expected to experience substantial expansion in the coming years, providing lucrative opportunities for industry players.

Request a Free Sample of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/endometrial-cancer-therapeutics-market/8953


         Endometrial Cancer Therapeutics Market Scope

Report Attribute Details
CAGR 4.8%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Type of Cancer, Type of Therapy, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The incidence of endometrial cancer has been on the rise globally, primarily due to factors such as increasing obesity rates, hormonal imbalances, and changes in lifestyle patterns. The growing awareness about early diagnosis and timely treatment has led to a surge in demand for effective therapeutics. Endometrial cancer therapeutics play a crucial role in managing the disease, improving patient outcomes, and enhancing quality of life.

Advancements in treatment modalities have significantly contributed to the market growth. Researchers and pharmaceutical companies are focusing on developing targeted therapies and immunotherapies that specifically address the underlying molecular abnormalities associated with endometrial cancer. These advancements provide opportunities for personalized treatment approaches, tailoring therapy based on individual patient characteristics and tumor profiles. Precision medicine and molecular profiling techniques enable clinicians to identify specific genetic alterations in tumors and select appropriate therapies, leading to improved treatment outcomes.

Furthermore, the market revenue is expanding with the emergence of novel treatment modalities such as immune checkpoint inhibitors and combination therapies. Immune checkpoint inhibitors, which enhance the body’s immune response against cancer cells, have shown promising results in clinical trials for advanced or recurrent endometrial cancer. Combination therapies that combine different treatment approaches, such as chemotherapy, targeted therapy, and immunotherapy, are being explored to improve response rates and overcome drug resistance.

Recent Development in the Endometrial Cancer Therapeutics Market: 

  • In February 2023, In the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial examining the efficacy of Context’s oral progesterone receptor antagonist onapristone extended-release (ONA-XR) in combination with anastrozole (ANA) to treat hormone receptor-positive (HR+) metastatic endometrial cancer (EC), Context Therapeutics Inc. reported that two patients had achieved a confirmed partial response (PR). In the current Phase 2 OATH clinical study, ONA-XR with ANA revealed a 4-month progression-free survival (PFS) rate of 77% and an overall response rate (ORR) of 22% in HR+ EC.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/endometrial-cancer-therapeutics-market/8953

Competitive Landscape

A list of the prominent players operating in the global market for endometrial cancer therapeutics includes: 

  • Eisai Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd

Prominent players in the endometrial cancer therapeutics market are actively engaged in clinical trials, collaborations, and strategic acquisitions to strengthen their product portfolios and expand their market presence. The competitive landscape is characterized by intense competition, with companies focusing on developing innovative therapies, improving treatment outcomes, and addressing the unmet needs of patients.

Regional Growth Dynamics: 

Based on this, North America accounts for a significant revenue share in the endometrial cancer therapeutics market, attributed to the presence of well-established healthcare infrastructure, increasing prevalence of endometrial cancer, and robust research and development activities. Europe is also a prominent market, driven by the growing awareness of endometrial cancer and favorable reimbursement policies. Additionally, the Asia Pacific is expected to exhibit rapid growth due to the increasing healthcare expenditure, improving access to healthcare services, and rising adoption of advanced therapeutics.

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8953


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Medical Device Analytical Testing Outsourcing Market by Service (Material Characterization, Extractable and Leachable), Application (Cardiology, Diabetes Care), End User (Hospitals, Homecare Setting)– Global Outlook & Forecast 2023-2031

Differentiated Thyroid Cancer Therapeutics Market by Therapy (Thyroid Stimulating Hormone Suppression, Chemotherapy), End User (Hospitals, Oncology Centers) – Global Outlook & Forecast 2023-2031

Medicated Feed Additives Market by Animal Type (Ruminants, Swine, Poultry), Type (Antibiotics, Vitamins, Antioxidants), Mixture Type (Supplements, Concentrates)– Global Outlook & Forecast 2023-2031

Rare Neurological Disease Treatment Market by Drug Type (Biologics, Small Molecules), Indication (Narcolepsy, Creutzfeldt-Jakob Disease, Multiple Sclerosis), Distribution Channel (Hospital Pharmacies, Retail Pharmacies)– Global Outlook & Forecast 2023-2031

Phototherapy Lamps and Units for Aesthetic Medicine Market by Modality (Fixed Units, Mobile Units), Source (Infrared Light, UV Light), End User (Skincare & Cosmetic Clinics, Hospitals)– Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech https://growthplusmedtechroundup.com/

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/  

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.